Stockscreener 앱 받기
0.76
0.65%
-0.005
시간 외 거래:
.77
0.01
+1.32%
전일 마감가:
$0.765
열려 있는:
$0.7544
하루 거래량:
2.81M
Relative Volume:
0.78
시가총액:
$206.66M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-2.8148
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+7.39%
1개월 성능:
+14.80%
6개월 성능:
-20.01%
1년 성능:
-42.86%
1일 변동 폭
$0.745
$0.78
1주일 범위
$0.681
$0.78
52주 변동 폭
$0.515
$2.06
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.76 | 206.66M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MyChesCo
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET - GuruFocus
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results | OCGN Stock News - GuruFocus
Ocugen, Inc. to Host Conference Call for Q1 2025 Financial Results and Business Update - Nasdaq
Ocugen to Host Conference Call on Friday, May 9 at 8:30 - GlobeNewswire
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results - TradingView
Gene Therapy Pioneer Ocugen Sets Q1 2025 Earnings Call to Reveal Blindness Treatment Progress - Stock Titan
Ocugen to Present at Eyecelerator Conference May 2025 - TipRanks
OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress - Ocugen
Stock Quote & Chart - Ocugen
Ocugen to Present on Modifier Gene Therapy Platform at Associati - GuruFocus
Ocugen, Inc. to Showcase Innovative Modifier Gene Therapy Platform at Upcoming ARVO and Retina World Congress Meetings - Nasdaq
Ocugen to Present on Modifier Gene Therapy Platform at - GlobeNewswire
Revolutionary Gene Therapy Platform: Ocugen Presents Phase 3 Trial Results for Multiple Eye Diseases - Stock Titan
O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Form DEF 14A Ocugen, Inc. For: Jun 05 - StreetInsider
Public market insider selling at Metro (MRU) - The Globe and Mail
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Insider Monkey
Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean - MyChesCo
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - Ocugen
Revolutionary Gene Therapy for Blindness: Ocugen Reveals Commercialization Strategy - Stock Titan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OCGN Stock Forecast: 2025-2035 Predictions - Exla Resources
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo
Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire
OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India
Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com
Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks
Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India
Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire
Ocugen seeks its One Shining Moment - The Healthcare Technology Report.
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):